Original p53 status predicts for pathological response in locally advanced breast cancer patients treated preoperatively with continuous infusion 5-fluorouracil and radiation therapy.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  International Journal of Radiation Oncology, Biology, Physics

• Publication date

  1997-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0360-3016(97)00506-3PMID 9392545
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Problems in evaluating response of primary breast cancer to systemic therapy

  2005cited by this paper
• Prognostic significance of p53 gene alterations in node-negative breast cancer

  2004cited by this paper
• The use of mammography in breast preservation in locally advanced breast cancer.

  1996cited by this paper
• P53 overexpression in head and neck carcinoma and radiotherapy results.

  1996cited by this paper
• Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value.

  1996cited by this paper
• p53 Protein expression or protein function? Re: Awwad et al. IJROBP 34(2):323–332; 1996

  1996cited by this paper
• Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy

  1995cited by this paper
• The role of cell cycle redistribution in radiosensitization: implications regarding the mechanism of fluorodeoxyuridine radiosensitization.

  1994cited by this paper
• Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast

  1994cited by this paper
• An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms

  1994cited by this paper
• Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery.

  1994cited by this paper
• Dependence of 5-fluorouracil-mediated radiosensitization on DNA-directed effects.

  1994cited by this paper
• Multidisciplinary management of advanced primary and metastatic breast cancer

  1994cited by this paper
• Ionizing radiation-induced cell death.

  1994cited by this paper
• p53 Mutations and c‐erbB‐2 Amplification in Intraductal and Invasive Breast Carcinomas of High Histologic Grade

  1993cited by this paper
• The importance of p53 gene alterations in human cancer: is there more than circumstantial evidence?

  1993cited by this paper
• Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor.

  1993cited by this paper
• Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells.

  1993cited by this paper
• Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer.

  1993cited by this paper
• Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation.

  1993cited by this paper
• p53-dependent apoptosis modulates the cytotoxicity of anticancer agents.

  1993cited by this paper
• The clinical rationale for S-phase radiosensitization in human tumors.

  1993cited by this paper
• High-risk breast cancer: Therapy

  1993cited by this paper
• p53, guardian of the genome

  1992cited by this paper
• Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers.

  1992cited by this paper
• Feasibility of breast‐conservation surgery after induction chemotherapy for locally advanced breast carcinoma

  1992cited by this paper
• Cancer. p53, guardian of the genome.

  1992cited by this paper
• Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.

  1992cited by this paper
• Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients.

  1992cited by this paper
• p53 mutations occur in aggressive breast cancer.

  1992cited by this paper
• Locally Advanced Breast Cancer: A Review Including the M.D. Anderson Experience

  1991cited by this paper
• The p53 tumour suppressor gene

  1991cited by this paper
• p53 mutations in human cancers.

  1991cited by this paper
• Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more.

  1990cited by this paper
• Locally advanced breast cancer current status and future directions.

  1989cited by this paper
• 5‐fluorouracil rechallenge by protracted infusion in refractory breast cancer

  1989cited by this paper
• Low‐dose continuous infusion 5‐fluorouracil. Evaluation in advanced breast carcinoma

  1989cited by this paper
• Definitive irradiation and chemotherapy for radiosensitization in management of anal carcinoma: interim report on Radiation Therapy Oncology Group study no. 8314.

  1989cited by this paper
• P53 expression in breast cancer

  1988cited by this paper
• Advanced primary breast cancer: assessment at mammography of response to induction chemotherapy.

  1988cited by this paper
• Radical radiotherapy alone in non-operable breast cancer: the major impact of tumor size and histological grade on prognosis.

  1988cited by this paper
• Results of a conservative treatment combining induction (neoadjuvant) and consolidation chemotherapy, hormonotherapy, and external and interstitial irradiation in 98 patients with locally advanced breast cancer (IIIA‐IIIB)

  1988cited by this paper
• Continuous 5-fluorouracil infusion in refractory carcinoma of the breast

  1987cited by this paper
• Principles and Practice of Radiation Oncology

  1987cited by this paper
• Pathological assessment of response to induction chemotherapy in breast cancer.

  1986cited by this paper
• Surgical adjuvant treatment of locally advanced breast cancer.

  1985cited by this paper
• Multimodal treatment of locoregionally advanced breast cancer

  1983cited by this paper
• Management of locally advanced carcinoma of the breast by primary radiation therapy.

  1983cited by this paper
• Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-Fluorouracil or ftorafur and X rays.

  1982cited by this paper
• Stage III Carcinoma of the Breast A Detailed Analysis

  1980cited by this paper
• Clinical dose-response curves of human malignant epithelial tumours.

  1973cited by this paper
• Combined effect of x radiation and 5-fluorouracil on survival of transplanted leukemic cells.

  1971cited by this paper
• Possible role of potentiators in radiation therapy.

  1961cited by this paper
• Possible role of potentiators in radiation therapy.

  1961cited by this paper
• Treatment of locally advanced carcinoma of the breast with roentgen therapy and simple mastectomy.

  1961cited by this paper
• Studies on fluorinated pyrimidines. II. Effects on transplanted tumors.

  1958cited by this paper

• Radioterapia/radioquimioterapia preoperatoria en cáncer de mama: nuevas perspectivas

  2023cites this paper
• Predictive Factors of Long-Term Survival after Neoadjuvant Radiotherapy and Chemotherapy in High-Risk Breast Cancer

  2022cites this paper
• Primary Chemoradiotherapy Treatment (PCRT) for HER2+ and Triple Negative Breast Cancer Patients: A Feasible Combination

  2022cites this paper
• Neoadjuvant Chemoradiation for Unfavourable Breast Cancer Patients: A Prospective Cohort Study

  2019cites this paper
• Concurrent Neoadjuvant Chemotherapy and Radiation Therapy in Locally Advanced Breast Cancer.

  2017cites this paper
• Results of a phase I–II study of adjuvant concurrent carboplatin and accelerated radiotherapy for triple negative breast cancer

  2017cites this paper
• Neoadjuvant chemotherapy followed by neoadjuvant concurrent chemoradiation for locally advanced breast cancer: a feasibility study and 10-year follow-up results

  2016cites this paper
• Comparison of two radiation techniques for the breast boost in patients undergoing neoadjuvant treatment for breast cancer.

  2016cites this paper
• Tumor RNA disruption predicts survival benefit from breast cancer chemotherapy

  2015cites this paper
• Phase II Clinical Trial of Concurrent Neoadjuvant Chemotherapy With Radiotherapy in Locally Advanced Breast Cancer

  2015cites this paper
• Efficacy of concurrent chemoradiotherapy for patients with locally recurrent or advanced inoperable breast cancer.

  2015cites this paper
• Analysis of pathological response after neoadjuvant chemoradiation in Stage III Breast Cancer.

  2014influential citation
• Concurrent chemo-radiotherapy in the treatment of early breast cancer: Current status

  2013cites this paper
• The fibroblast growth factor receptor 1 (FGFR1), a marker of response to chemoradiotherapy in breast cancer?

  2012cites this paper
• Preoperative radio-chemotherapy in early breast cancer patients: long-term results of a phase II trial.

  2012cites this paper
• Inhibition of p53 sensitizes MCF-7 cells to ceramide treatment.

  2010cites this paper
• Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: pathologic response correlates with five-year overall survival

  2010cites this paper
• Deletion of p53 in human mammary epithelial cells causes chromosomal instability and altered therapeutic response

  2010cites this paper
• Combining systemic therapies with radiation in breast cancer.

  2009cites this paper
• Concurrent use of chemotherapy or novel agents in combination with radiation in breast cancer

  2009cites this paper
• Local control by radiotherapy: is that all there is?

  2008cites this paper
• Combining chemotherapy with radiation in breast cancer

  2008cites this paper
• Selective mastectomy in the management of locally advanced breast cancer.

  2007cites this paper
• p53 as a Prognostic and Predictive Indicator

  2006influential citation
• Pathological response to preoperative concurrent chemo-radiotherapy for breast cancer: results of a phase II study.

  2006cites this paper
• [Role of radiation therapy on the use of primary ("neoadjuvant") systemic treatment of breast cancer].

  2006cites this paper
• Neoadjuvant Concurrent Paclitaxel and Radiation in Stage II/III Breast Cancer

  2006cites this paper
• Radiotherapie im Konzept der primären („neoadjuvanten“) systemischen Behandlung des Mammakarzinoms

  2006cites this paper
• Concurrent Radiotherapy and Taxane Chemotherapy in Patients with Locoregional Recurrence of Breast Cancer

  2006cites this paper
• In regard to Kao et al.: concomitant radiation therapy and paclitaxel for unresectable locally advanced breast cancer: results from two consecutive phase I/II trials (Int J Radiat Oncol Biol Phys 2005;61:1045-1053).

  2005cites this paper
• Concomitant radiation therapy and paclitaxel for unresectable locally advanced breast cancer: results from two consecutive phase I/II trials.

  2005cites this paper
• Only grading has independent impact on breast cancer survival after adjustment for pathological response to preoperative chemotherapy

  2004cites this paper
• The impact of progesterone receptor in prediction of complete pathological response to preoperative chemotherapy in primary breast cancer patients

  2004cites this paper
• [Does primary chemotherapy really increase the rate of breast conserving treatments?].

  2004cites this paper
• Cancer du sein. Traitements néo–adjuvants. Radiothérapie náo–adjuvante ou radio–chimiothárapie néo-adjuvante

  2004cites this paper
• Docetaxel and cisplatin as primary chemotherapy for treatment of locally advanced breast cancers.

  2004cites this paper
• La chimiothérapie première permet-elle réellement d’augmenter le taux de conservation mammaire ?

  2004cites this paper
• Mutation and accumulation of p53 related to results of adjuvant therapy of postmenopausal breast cancer patients

  2004cites this paper
• P7 antigen expression in human breast cancer.

  2003cites this paper
• Optimized polymerase chain reaction-based single-strand conformation polymorphism analysis of p53 gene applied to Bulgarian patients with invasive breast cancer

  2003cites this paper
• TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer.

  2003cites this paper
• Preoperative twice-weekly paclitaxel with concurrent radiation therapy followed by surgery and postoperative doxorubicin-based chemotherapy in locally advanced breast cancer: a phase I/II trial.

  2003cites this paper
• Antigen Expression in Human Breast Cancer 1

  2003cites this paper
• Combined modality management of breast cancer: development of predictive markers through proteomics.

  2003cites this paper
• Gene Mutations Predict the Response to Neoadjuvant Treatment with 5-Fluorouracil and Mitomycin in Locally Advanced Breast Cancer

  2003cites this paper
• Study of suboptimum treatment response: lessons from breast cancer.

  2003cites this paper
• Combined Modality Therapy in Locally Advanced Breast Cancer

  2003cites this paper
• Low HER2/neu gene expression is associated with pathological response to concurrent paclitaxel and radiation therapy in locally advanced breast cancer.

  2002cites this paper
• Radiation-induced cell cycle delays and p53 status of early passage melanoma cell lines.

  2001cites this paper
• Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy.

  2001cites this paper
• [Predictive and prognostic factors in breast cancer evaluated by immunohistological methods].

  2001cites this paper
• Taxanes in combined modality therapy for solid tumors.

  2001cites this paper
• Influence of TP 53 Gene Alterations and c-erbB2 Expression on the Response to Treatment with Doxorubicin in Locally Advanced Breast Cancer 1

  2001cites this paper
• Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.

  2001cites this paper
• Tp53 gene therapy: a key to modulating resistance to anticancer therapies?

  2000cites this paper
• The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2.

  2000influential citation
• Molecular predictive factors for local recurrence and distant metastasis of breast cancer after lumpectomy with postoperative radiation therapy.

  2000cites this paper
• Clinicopathologic Analysis of Fas, Fas Ligand, and Other Biomarkers in Locally Advanced Breast Carcinoma

  2000cites this paper
• Does p53 status influence tumor response to anticancer therapies?

  2000cites this paper
• Concurrent paclitaxel and radiation therapy for breast cancer.

  1999cites this paper
• An update on radiation therapy in breast cancer.

  1999cites this paper
• Clinical studies of p53 in treatment and benefit of breast cancer patients.

  1999cites this paper
• The role of the p53 tumour suppressor gene in human breast cancer.

  1999cites this paper
• Metastatic site and p53 primary tumor expression in previously untreated stage IV breast cancer patients.

  1999cites this paper
• Pre-treatment anaemia alters outcome in early squamous cell carcinoma of the larynx treated by radical radiotherapy

  1999cites this paper
• BREAST RADIATION THERAPY

  1999cites this paper
• Clinical studies of p 53 in treatment and benefit of breast cancer patients

  1999influential citation
• Clinical implications of p53 mutations

  1999cites this paper
• Taxanes in combined-modality therapy for solid tumors.

  1999cites this paper
• High-dose chemotherapy: how resistant is breast cancer?

  1998cites this paper
• P53 and breast cancer.

  1993cites this paper